Ozempic Lawsuit Highlights Vision Loss Claims
Tap title to read story
In 2023, a Maryland resident began using Ozempic to manage diabetes, a drug also popular for weight loss. About four months later, he was diagnosed with non‑arteritic anterior ischemic optic neuropathy, an eye stroke that can cause sudden vision loss.
On New Year’s Eve, 2024, he reported total blindness in one eye, and ten months later, the other eye was affected. He stopped the medication after the second loss and filed a lawsuit against Novo Nordisk, alleging the company failed to warn patients of the risk. The case joins hundreds of similar claims against GLP‑1 drugs, raising questions about safety disclosures and regulatory oversight.
The lawsuit underscores the tension between therapeutic benefits and rare but severe side effects. It also highlights the need for clearer communication from manufacturers and healthcare providers. As more patients report similar incidents, the legal and medical communities face pressure to reassess risk‑
Timeline
- 2023 — Patient began Ozempic for diabetes management
- On October 1 2024 Second eye lost vision ten months after first incident.
- On March 24 2026 Lawsuit update cites growing number of GLP‑1 related claims.
Sources
JQJO Editorial Desk · Human reviewed · AI assisted. Report a correction.



















